Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo® - GlobeNewswire

Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®  GlobeNewswire

JATENZO® is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult hypogonadal ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more